Molecular Docking and Binding Mode Analysis of Plant Alkaloids as in vitro and in silico Inhibitors of Trypanothione Reductase from Trypanosoma cruzi

被引:1
作者
Argueelles, Alonso J. [1 ]
Cordell, Geoffrey A. [1 ,2 ,3 ]
Maruenda, Helena [1 ]
机构
[1] Pontificia Univ Catolica Peru, Dept Ciencias, Secc Quim, Lima, Peru
[2] Nat Prod Inc, Evanston, IL 60203 USA
[3] Univ Florida, Coll Pharm, Dept Pharmaceut, Gainesville, FL 32610 USA
关键词
Chagas disease; Trypanothione reductase; Molecular docking; Inhibition; Alkaloids; Binding conformation; RATIONAL DRUG DESIGN; NATURAL-PRODUCTS; GLUTATHIONE-REDUCTASE; CRYSTAL-STRUCTURE; SITE; PHENOTHIAZINES; METABOLISM; DISCOVERY; DATABASE; TARGET;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Trypanothione reductase (TryR) is a key enzyme in the metabolism of Trypanosoma cruzi, the parasite responsible for Chagas disease. The available repertoire of TryR inhibitors relies heavily on synthetic substrates of limited structural diversity, and less on plant-derived natural products. In this study, a molecular docking procedure using a Lamarckian Genetic Algorithm was implemented to examine the protein-ligand binding interactions of strong in vitro inhibitors for which no X-ray data is available. In addition, a small, skeletally diverse, set of natural alkaloids was assessed computationally against T. cruzi TryR in search of new scaffolds for lead development. The preferential binding mode (low number of clusters, high cluster population), together with the deduced binding interactions were used to discriminate among the virtual inhibitors. This study confirms the prior in vitro data and proposes quebrachamine, cephalotaxine, cryptolepine, (22S,25S)-tomatidine, (22R,25S)-solanidine, and (22R,25R)-solasodine as new alkaloid scaffold leads in the search for more potent and selective TryR inhibitors.
引用
收藏
页码:57 / 62
页数:6
相关论文
共 34 条
  • [1] Austin S E, 1999, Drug Des Discov, V16, P5
  • [2] Beig M, 2013, DRUG DISCOV INFEC DI, P385
  • [3] RATIONALLY DESIGNED SELECTIVE INHIBITORS OF TRYPANOTHIONE REDUCTASE - PHENOTHIAZINES AND RELATED TRICYCLICS AS LEAD STRUCTURES
    BENSON, TJ
    MCKIE, JH
    GARFORTH, J
    BORGES, A
    FAIRLAMB, AH
    DOUGLAS, KT
    [J]. BIOCHEMICAL JOURNAL, 1992, 286 : 9 - 11
  • [4] Trypanosomatidae Diseases: From the Current Therapy to the Efficacious Role of Trypanothione Reductase in Drug Discovery
    Bernardes, L. S. C.
    Zani, C. L.
    Carvalho, I.
    [J]. CURRENT MEDICINAL CHEMISTRY, 2013, 20 (21) : 2673 - 2696
  • [5] Crystal structure of Trypanosoma cruzi trypanothione reductase in complex with trypanothione, and the structure-based discovery of new natural product inhibitors
    Bond, CS
    Zhang, YH
    Berriman, M
    Cunningham, ML
    Fairlamb, AH
    Hunter, WN
    [J]. STRUCTURE, 1999, 7 (01) : 81 - 89
  • [6] BRUSH S, 1995, CONSERV BIOL, V9, P1189, DOI 10.1046/j.1523-1739.1995.9051176.x-i1
  • [7] Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs
    Chan, C
    Yin, H
    Garforth, J
    McKie, JH
    Jaouhari, R
    Speers, P
    Douglas, KT
    Rock, PJ
    Yardley, V
    Croft, SL
    Fairlamb, AH
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (02) : 148 - 156
  • [8] Ecopharmacognosy and the responsibilities of natural product research to sustainability
    Cordell, Geoffrey A.
    [J]. PHYTOCHEMISTRY LETTERS, 2015, 11 : 332 - 346
  • [9] Natural Products and Traditional Medicine: Turning on a Paradigm
    Cordell, Geoffrey A.
    Colvard, Michael D.
    [J]. JOURNAL OF NATURAL PRODUCTS, 2012, 75 (03): : 514 - 525
  • [10] Charge is the major discriminating factor for glutathione reductase versus trypanothione reductase inhibitors
    Faerman, CH
    Savvides, SN
    Strickland, C
    Breidenbach, MA
    Ponasik, JA
    Ganem, B
    Ripoll, D
    KrauthSiegel, RL
    Karplus, PA
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 1996, 4 (08) : 1247 - 1253